{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:15:21Z","timestamp":1793423721234,"version":"4.5.0"},"reference-count":65,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Rosacea is a chronic inflammatory skin condition affecting approximately 5.5% of the global population. Patients present heterogeneously with a mix of features in the central facial region, of which papules and pustules are considered to be a major feature. The identification of effective treatments for reducing inflammatory lesions in rosacea can alleviate the psychosocial burden that many rosacea patients experience, including reduced self-esteem, anxiety, and social withdrawal. The objective of this systematic review is to determine the effectiveness of topical and systemic therapies in reducing lesion count in rosacea patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/Results:<\/jats:title>\n                    <jats:p>Medline, Embase, and Cochrane CENTRAL databases were searched, resulting in the inclusion of 43 clinical trials reporting on a total of 18,347 rosacea patients. The most well-studied treatments include ivermectin, metronidazole, azelaic acid, minocycline, and doxycycline. Oral isotretinoin was the most effective treatment in reducing inflammatory lesions and may be recommended for severe recalcitrant cases of rosacea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Several topical and systemic therapies have demonstrated efficacy in reducing inflammatory lesion count in rosacea patients, with mechanisms of action centred around suppressing inflammation and killing\n                      <jats:italic toggle=\"yes\">Demodex folliculorum<\/jats:italic>\n                      mites. Additional research is required to determine effective combination therapies in rosacea.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/12034754241253195","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T02:07:26Z","timestamp":1716948446000},"page":"352-359","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of Treatments in Reducing Inflammatory Lesion Count in Rosacea: A Systematic Review"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-095X","authenticated-orcid":false,"given":"Ryan S. Q.","family":"Geng","sequence":"first","affiliation":[{"name":"Temerty School of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-5961","authenticated-orcid":false,"given":"Siddhartha","family":"Sood","sequence":"additional","affiliation":[{"name":"Temerty School of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8503-0056","authenticated-orcid":false,"given":"Nicholas","family":"Hua","sequence":"additional","affiliation":[{"name":"Temerty School of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chen","sequence":"additional","affiliation":[{"name":"Temerty School of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6060-7272","authenticated-orcid":false,"given":"Ronald G.","family":"Sibbald","sequence":"additional","affiliation":[{"name":"Dalla Lana School of Public Health and Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[{"name":"Division of Pediatric Dermatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16481"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03472.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.043"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15122"},{"issue":"6","key":"e_1_3_2_6_2","first-page":"348","article-title":"Burden of disease: the psychosocial impact of rosacea on a patient\u2019s quality of life","volume":"6","author":"Huynh TT.","year":"2013","unstructured":"Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient\u2019s quality of life. Am Health Drug Benefits. 2013;6(6):348-354.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082153"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2528"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18049"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02130.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","unstructured":"Bjerke R Fyrand O Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. 1999;79(6):456-459. doi:10.1080\/000155599750009906","DOI":"10.1080\/000155599750009906"},{"key":"e_1_3_2_13_2","article-title":"Randomized, phase III, double-blind, vehicle-controlled clinical trial to evaluate the safety and efficacy of 12 weeks of twice-daily azelaic acid foam, 15% in papulopustular rosacea","volume":"72","author":"Draelos ZD","year":"2015","unstructured":"Draelos ZD, Elewski BE, Harper JC, et al. Randomized, phase III, double-blind, vehicle-controlled clinical trial to evaluate the safety and efficacy of 12 weeks of twice-daily azelaic acid foam, 15% in papulopustular rosacea. J Am Acad Dermatol. 2015;72(5 Suppl. 1):AB59.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.11.1444"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02940.x"},{"key":"e_1_3_2_16_2","author":"NCT","year":"2012","unstructured":"NCT. Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea. 2012.","journal-title":"Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea"},{"issue":"3","key":"e_1_3_2_17_2","first-page":"187","article-title":"Investigator-reported efficacy of azelaic acid foam 15% in patients with papulopustular rosacea: secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial","volume":"98","author":"Solomon JA","year":"2016","unstructured":"Solomon JA, Tyring S, Staedtler G, Sand M, Nkulikiyinka R, Shakery K. Investigator-reported efficacy of azelaic acid foam 15% in patients with papulopustular rosacea: secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial. Cutis. 2016;98(3):187-194.","journal-title":"Cutis"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.308"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02283.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.6.659"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.021"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.023"},{"key":"e_1_3_2_23_2","author":"NCT","year":"2017","unstructured":"NCT. A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules. 2017.","journal-title":"A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules"},{"issue":"12","key":"e_1_3_2_24_2","first-page":"16","article-title":"Minocycline extended-release comparison with doxycycline for the treatment of rosacea: a randomized, head-to-head, clinical trial","volume":"14","author":"Tsianakas A","year":"2021","unstructured":"Tsianakas A, Pieber T, Baldwin H, et al. Minocycline extended-release comparison with doxycycline for the treatment of rosacea: a randomized, head-to-head, clinical trial. J Clin Aesthet Dermatol. 2021;14(12):16-23.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.025"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1204"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1986.tb04533.x"},{"key":"e_1_3_2_28_2","author":"Euctr HU.","year":"2010","unstructured":"Euctr HU. A Double Blind, Vehicle Controlled, Parallel Group Study Assessing the Activity of Cd5024 1% Cream in Subjects With Papulopustular Rosacea Over 12 Weeks Treatment. 2010.","journal-title":"A Double Blind, Vehicle Controlled, Parallel Group Study Assessing the Activity of Cd5024 1% Cream in Subjects With Papulopustular Rosacea Over 12 Weeks Treatment"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12480"},{"issue":"3","key":"e_1_3_2_30_2","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: Results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Gold LS","year":"2014","unstructured":"Gold LS, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: Results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316-323.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_31_2","author":"NCT","year":"2016","unstructured":"NCT. Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea. 2016.","journal-title":"Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0133-6"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13408"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808702100410"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259203"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660290077020"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.116219"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03427.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065849"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16254"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-001-0144-4"},{"issue":"6","key":"e_1_3_2_42_2","first-page":"357","article-title":"Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea","volume":"75","author":"Torok HM","year":"2005","unstructured":"Torok HM, Webster G, Dunlap FE, Egan N, Jarratt M, Stewart D. Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. Cutis. 2005;75(6):357-363.","journal-title":"Cutis"},{"issue":"1","key":"e_1_3_2_43_2","first-page":"73","article-title":"The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea","volume":"79","author":"Wolf JE","year":"2007","unstructured":"Wolf JEJr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79(1):73-80.","journal-title":"Cutis"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Del Rosso JQ Stein Gold L Kircik L et al. Integrated safety and efficacy analysis of FMX103 1.5% topical minocycline foam for the treatment of moderate-to-severe papulopustular rosacea: results from two Phase III studies. 2021;14(5 Suppl. 1):S30.","DOI":"10.25251\/skin.4.supp.54"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.043"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.886"},{"issue":"3","key":"e_1_3_2_47_2","first-page":"292","article-title":"Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea","volume":"12","author":"Jackson JM","year":"2013","unstructured":"Jackson JM, Kircik LH, Lorenz DJ. Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea. J Drugs Dermatol. 2013;12(3):292-298.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0339-0"},{"key":"e_1_3_2_49_2","author":"NCT","year":"2020","unstructured":"NCT. A Pilot Study on the Use of Seysara for Rosacea. 2020.","journal-title":"A Pilot Study on the Use of Seysara for Rosacea"},{"key":"e_1_3_2_50_2","article-title":"Efficacy and safety of FMX103 (1.5% minocycline foam) in the treatment of moderate-to-severe papulopustular rosacea: results from two Phase III randomized, multicenter, double-blind, vehicle controlled studies","volume":"12","author":"Stein Gold L","year":"2019","unstructured":"Stein Gold L, Del Rosso JQ, Bhatia ND, Hooper D, Nahm W, Stuart I. Efficacy and safety of FMX103 (1.5% minocycline foam) in the treatment of moderate-to-severe papulopustular rosacea: results from two Phase III randomized, multicenter, double-blind, vehicle controlled studies. J Clin Aesthet Dermatol. 2019;12(5 Supplement 1):S32.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18857"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08496.x"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(99)70085-x"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1789050"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.3.9364"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.123498"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18468"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12580370"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.14"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1177\/1099800409346333"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08028.x"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2020.04.011"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02125.x"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.59.8.0010"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.05.019"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.063"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241253195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/12034754241253195","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/12034754241253195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:50:43Z","timestamp":1777391443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/12034754241253195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/12034754241253195"],"URL":"https:\/\/doi.org\/10.1177\/12034754241253195","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}